T-cell large granular lymphocytic leukemia, a rare clonal cancer with indolent growth characteristics, is often associated with autoimmune disease and neutropenia. According to an international group of collaborators, 40% of patients have somatic mutations that activate STAT3.

Induction chemotherapy fails to induce a complete remission in only about 2 to 3% of children with ALL. In an analysis of more than 1000 such patients, the authors defined subgroups with a favorable prognosis and those with an unfavorable prognosis.

Malignant cells in most patients with acute myeloid leukemia have mutations. Cytogenetic classification yields some prognostic information, but the intermediate-risk group is heterogeneous. Mutational analysis identifies intermediate-risk patients who may benefit from high-dose therapy.

Whole-genome sequencing of samples from seven subjects with secondary acute myeloid leukemia identified somatic mutations. These data, together with genotype analysis of the antecedent myelodysplastic syndromes (MDS), revealed the clonal evolution of MDS and secondary AML.

In patients with limited-stage Hodgkin's disease, ABVD chemotherapy alone resulted in a higher rate of long-term (12-year) survival than either radiation therapy alone or radiation therapy plus ABVD chemotherapy, with significantly fewer late treatment-related deaths.

CLL is a heterogeneous disease with a variable clinical course and response to therapy. New genetic lesions have been noted in subgroups of patients through whole-exome and whole-genome sequencing. An abnormality in RNA splicing has been found in 15% of patients.

The introduction of a transgene into human donor T cells that can kill the cells when dimerization is induced by a pharmacologic agent has improved prospects for the exploitation of T-cell graft-versus-tumor effects while controlling graft-versus-host disease.